SCHEMBL3072205

SCHEMBL3072205

COc1ccc(Cl)cc1-c1cncc(C(=O)O)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALPL P05186 4/20 0.57
CTSA P10619 3/20 0.53
TBXA2R P21731 1/20 0.53
PTGER1 P34995 1/20 0.53
HPGD P15428 3/20 0.52
ALDH1A1 P00352 2/20 0.52
TTR P02766 1/20 0.49
HCAR2 Q8TDS4 1/20 0.49
CYP1A1 P04798 1/20 0.48
CYP1B1 Q16678 1/20 0.48
ERN1 O75460 1/20 0.47
MAPK1 P28482 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MKNK1 Q9BUB5 1/20 0.44
MKNK2 Q9HBH9 1/20 0.44
PLG P00747 1/20 0.44
PLAU P00749 1/20 0.44
ABL1 P00519 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4350002 0.86 CTSA (0.54) ALPLCTSAHCAR2CYP1A1CYP1B1
SCHEMBL2410383 0.85 ALDH1A1 (0.57) CTSAPTGER1HPGDALDH1A1TTR
SCHEMBL23013093 0.83 CTSA (0.56) CTSATBXA2RPTGER1HPGDALDH1A1
SCHEMBL29508472 0.83 CTSA (0.56) CTSATBXA2RPTGER1HPGDALDH1A1
SCHEMBL2406330 0.82 PTGER1 (0.59) CTSAPTGER1HPGDALDH1A1TTR
SCHEMBL25239407 0.81 HCAR2 (0.56) CTSATBXA2RPTGER1ALDH1A1HCAR2
SCHEMBL1812435 0.81 KMO (0.55) ALPLTTRHCAR2CYP1A1CYP1B1
SCHEMBL19418726 0.80 CYP11B1 (0.52) ALPLCTSAHPGDALDH1A1CYP1A1
SCHEMBL27747553 0.78 KMO (0.55) ALPLHCAR2CYP1A1CYP1B1MKNK1
SCHEMBL21044491 0.77 ALDH1A1 (0.55) CTSAHPGDALDH1A1TTRERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150093356-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2015-04-02 US disclosed
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 US disclosed
US-7790704-B2 Thrombopoietin mimetics GlaxoSmithKline, LLC (US) 2010-09-07 US disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 EP disclosed
EP-1864981-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-07-22 EP disclosed
US-20090155203-A1 THROMBOPOIETIN MIMETICS SmithKline Bee cham Corporation 2009-06-18 US disclosed
CN-101342169-A Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-01-14 CN disclosed
CN-100423721-C Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2008-10-08 CN disclosed
US-7335649-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2008-02-26 US disclosed
EP-1889838-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2008-02-20 EP disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 EP disclosed
US-20070179192-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED 2007-08-02 US disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP disclosed
CN-1444477-A Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2003-09-24 CN disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK ALPL 3629/4885CTSA 1667/4885TBXA2R 10/4885
US-20070179192-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK ALPL 3629/4885CTSA 1667/4885TBXA2R 10/4885
US-20150093356-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK ALPL 3629/4885CTSA 1667/4885TBXA2R 10/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK ALPL 3629/4885CTSA 1667/4885TBXA2R 10/4885
US-20090155203-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK ALPL 3629/4885CTSA 1667/4885TBXA2R 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.